IE47606B1 - Absorbable hemostatic composition - Google Patents
Absorbable hemostatic compositionInfo
- Publication number
- IE47606B1 IE47606B1 IE2393/78A IE239378A IE47606B1 IE 47606 B1 IE47606 B1 IE 47606B1 IE 2393/78 A IE2393/78 A IE 2393/78A IE 239378 A IE239378 A IE 239378A IE 47606 B1 IE47606 B1 IE 47606B1
- Authority
- IE
- Ireland
- Prior art keywords
- composition
- powder
- hemostatic
- weight
- collagen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- 102000009123 Fibrin Human genes 0.000 claims abstract description 17
- 108010073385 Fibrin Proteins 0.000 claims abstract description 17
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 229950003499 fibrin Drugs 0.000 claims abstract description 17
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- -1 poly(alkylene) Polymers 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002201 Oxidized cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000512 collagen gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940107304 oxidized cellulose Drugs 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims 2
- 229920001484 poly(alkylene) Polymers 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052782 aluminium Inorganic materials 0.000 abstract description 3
- 239000004033 plastic Substances 0.000 abstract description 3
- 229920003023 plastic Polymers 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 description 29
- 239000001993 wax Substances 0.000 description 20
- 239000000565 sealant Substances 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical class CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
- A61F2310/00377—Fibrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Abstract
An absorbable hemostatic surgical composition for the control of osseous hemorrhage comprising from 10 to 50 percent by weight of a hemostatic powder comprising a mixture of fibrin and collagen powders in a water-soluble, biocompatible base containing a tackifying agent. A preferred formulation contains approximately equal proportions of fibrin and collagen in an aqueous glycerol base and is a putty-like semisolid which when packaged in a syringe, plastic envelope, or aluminum tube, may be extruded from the package as required for use.
Description
This invention, relates to a bone sealant, and more particularly, to an absorbable, semisolid composition for the con5 trol of osseous hemorrhage.
Various substances and compositions have been employed by members of the medical profession to control the bleeding from cut bone surfaces. One class of materials used for the con trol of this type of hemorrhage is called bone wax. Bone waxes are used for the purpose of controlling hemorrhages from the cut surfaces of bones, such as those of the skull, by forcibly smear ing the wax over the out surface so that the material acts mechanically to occlude and seal the open ends of the bleeding osseous vessels and sinuses.
Bone waxes used in surgery today are generally prepared from refined beeswax which has been admixed with other nonabsorbable and water insoluble hydrocarbons and vegetable oils. Certain disadvantages inhere in these bone wax compositions, as for example, relatively poor adhesion properties, separation of wax components and the hard, brittle state of the wax at room temperatures requiring use at elevated temperatures.
U.S. Patent No. 3,395,217 discloses nonabsorbable bone wax compositions comprised of low molecular weight ethylene oo25 polymer waxes containing from about 15 to about 40 percent by weight of another unsaturated constituent and having molecular -2476 0 6 weights in the range of 1000 to 4000. These waxes have a semisolid consistency such that they can be kneaded between the fingers when at room temperature and have the right amount of tack and adhesion so that they can be easily manipulated in the hands of the surgeon or applied by any suitable applicator suoh as a gloved finger, spatula or appropriate disposable applicator.
Absorbable bone waxes have also been suggested. U.S. Patent No. 2,772,999 describes a bone wax comprised of a water soluble innocuous base and free acid cellulose glycolic acid ether or free acid cellulose hydroxypropionic acid ether as a hemostatic agent. The composition also preferably contains a tackifier such as cellulose glycolic aoid ether salt or cellulose hydroxypropionic acid ether salt (preferably sodium salt) and water as a plasticizer.
The Annals of Surgery 132, 1128 (1950) describes an absorbable hemostatic bone wax containing powdered oxidized cellulose as the hemostatic agent in a base of polyethylene glycol.
The base is a mixture of high and low molecular weight polyethylene glycols selected to provide the malleability and con20 sistency of material desired for this application.
The present invention provides a new absorbable bone sealant which is a putty-like semisolid at room temperature.
The softness of the composition allows the material to be packaged in a syringe, plastic or coated paper envelope, or aluminum or glass tube from which it may be extruded or dispensed in desired amounts during use. The sealant has sufficient tack so that it adheres to bone surfaces, yet is easily manipulated in the hands of the surgeon without crumbling or sticking to the surgeon's gloves. -347606 Absorbable bone sealant compositions of the present invention comprise a mixture of from 10 to 50 percent by weight of the total composition of a hemostatic powder in a water-soluble bicompatible base, optionally contain5 ing a small amount of tackifying agent, the hemostatic powder comprising a mixture of fibrin and collagen powders, preferably in substantially equal proportions. The base is preferably a mixture of water and a poly-ol such as glycerol, and the tackifying agent, if present, is prefer10 ably a polyglucoside such as dextran. The sealant is formulated to the consistency of a semisolid which is extrudable from a large orifice syringe. The composition is packaged in a syringe, plastic envelope, or aluminum tube and sterilized by radiation. During use, small amounts of the sealant may be exturded from the package as required by the surgeon. The composition is effective to control osseous hemorrhage from cut bone and does not interfere with subsequent healing and rejoining of bone parts.
It is desirable that hemostatic compositions of the present invention, which comprise a mixture of a hemostatic powder, an innocuous absorbable base, and,preferably, a tackifying agent should be formulated to obtain a semisolid material which may be readily spread upon the surface of cut bone in order to arrest the flow of blood.
Fibrin powder useful in the present invention may be ob tained from human or animal blood according to the method disclosed in U.S. Patent No. 3,523,807. - 4 47606 . The fibrin powder is preferably reduced to a particle size of 500 microns or smaller, and most preferably to a size of about 200 microns. The fibrin powder thus obtained comprises,together with the collagen powder, fraa IG to 50 percent hy weight of the total hemostatic canpositiai.
Collagen powder, useful in the present invention, is a finely divided, fluffy material which may be prepared according to the method disclosed in U.S. Patent No. 3,742,955.
The collagen powder is preferably reduced to a particle size of 2 mm or less, and most preferably to less than 1 mm.
The collagen powder and fibrin pcwder are preferably mixed in a ratio of 40-95 percent by weight fibrin, 5-60 percent by weight collagen, in order to obtain a final product having the desired characteristics of softness and malleability. In a particularly preferred composition of this invention, substantially equal proportions of fibrin and collagen powders are used with good results. 2o The base component of the hemostatic composition may be an aqueous solution of a single substance or a mixture of two or more water-soluble innocuous substances. Substances suitable as bases include nonvolatile compatible poly-ol compounds such as glycerol, propylene glycol, polymerized low molecular weight aliphatic glycols such as polymerized ethylene glycol and low molecular weight ethers or esters of polyglycols such as the -547606 methyl, ethyl, or propyl ethers of polyethylene glycols and the acetic or propionic esters of polyethylene or polypropylene glycols. Glycerol and polyethylene glycols are the preferred base materials, and polymerized ethylene glycols having a molecular weight in the range of 200 to 4000 and a consistency varying from a liquid of low viscosity to that of a waxy solid may be found suitable. If desired, a polymerized ethylene glycol having a molecular weight of 1000 to 4000 may be used in combination with a polymerized ethylene glycol having a molecular weight of 200 to 600.
In addition to the hemostatic agent and innocuous base, the bone wax composition may also contain a tackifier such as a polyglucoside, gelatin or collagen gel polyvinyl pyrrolidone, cellulose ester- or other derivative of cellulose such as oxi15 dized cellulose, a water-soluble starche, or a sugar. A preferred polyglucoside is dextran while a preferred cellulose derivative is cellulose glycolic acid ether salt or cellulose hydroxypropionic acid ether salt, most preferably the sodium salt The powdered fibrin hemostatic material and. tackifying agent, if 20 present, should desirably he thoroughly -dispersed in the aqueous base to provide a semisolid canpositicn which is readily spreadable cn the surface of cut bone. The desired consistency of the composition is obtained by proper selection of the base material and the amount of water admixed therewith.
The following examples are provided to further illustrate preferred embodiments of the present invention: -647606 EXAMPLE I A hemostatic composition was prepared by thoroughly dispersing the following materials in the indicated proportions: Hemostatic Agent Fibrin powder (200 microns) - 17.5 g Collagen powder (2 mm) - 17.5 g Tackifying Agent Dextran (MW 60,000-90,000) - 8.0 g Base Glycerol - 30.0 g Water - 27.0 g Total . 100 g The composition had a semisolid, putty-like, slightly sticky consistency. When loaded in a 1 cc hypodermic syringe with the needle removed, the mixture was readily extruded through the 1.6 mm diameter opening of the syringe to form a ribbon of ’ material ready for use.
EXAMPLE II An extruded ribbon, 10 mm in length by 1.6 mm in diameter of the hemostatic composition of Example I was implanted in the lumbar muscles of 12 CFY strain rats weighing 250-300 kg. Two rats were sacrificed after 3, 7, 14, 28, 49, and 70 days, and the implant sites examined to determine absorption rates and tissue reaction to the bone sealant. The bone sealant was substantially completely absorbed by the 14th day with only few remnants of collagen being detectable. No trace of the sealant was found after 28 days. No abnormal tissue reaction was ob20 served during the test. -747606 EXAMPLE III Fourteen white male CFY rats, weighing 200-250 g, were anesthetized, and under surgically sterile conditions, the frontal and parietal bones of the skull were exposed. Four holes were made, one in each quadrant of the skull, using a 2 mm burr on an electric drill. The parietal hole on one side was filled with a complete plug of the bone sealant of Example I, and the parietal hole on the other side plugged with a commercial bone wax control. One frontal hole was treated by spreading a small amount o'f the bone sealant of Example I on the cut surface, while the other hole was similarly treated with the bone wax control.
After 14 days, 12 rats were sacrificed and the wounds examined to determine the histological effects of the bone sealant and bone wax. The remaining 2 rats were sacrificed and ex15 amined after 28 days. The following results were noted with no significant differences between the 14- and 28-day examination periods. -847606 A. Bone Sealant of Example I i. Plugged holes. Holes filled with tissue and bony edges lined with a layer of osteoblasts. There was considerable evi5 dence of new bone formation in the area. ii. Smeared holes. Similar to plugged holes, but connective tissue depressed below the level of the skull surface.
B. Bone Wax Control i. Plugged holes. Holes remained filled with a solid plug of wax which was easily removed. Hole was thickly roofed by connective tissue with evidence of a much thinner tissue floor. There was no indication of any significant tissue activity in plug area. ii. Smeared holes. Generally filled with connective tissue, but with fragments of wax visible in many cases.
The composition of Example I is a specific illustration of a generally preferred hemostatic composition having the following range of formulation: Fibrin powder - 15-25% Collagen powder - 15-25% Dextran - 5-10% Glycerol - 20-40% Water - 20-30% The precise composition illustrated in Example I was selected from the above general formulation to provide a desir30 able combination of properties, particularly consistency and adhesion or tack. Optimum formulations may vary somewhat from that given in Example I depending upon the particular properties of the individual ingredients.
Claims (8)
1. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising from 10 to 50 percent by weight of the total composition of a hemostatic pcwder in a water-soluble, biocanpatible base, said hemostatic powder comprising a mixture of fibrin 5 and collagen powders.
2. The composition of Claim 1 wherein the particle size of the fibrin powder is less than about 500 microns, and the particle size of the collagen powder is less than about 2 mm.
3. The composition of Claim 1 wherein said biocompat10 ible base comprises a mixture of water and a poly-ol.
4. The composition of Claim 3 wherein said poly-ol is selected from the group consisting of glycerol, propylene glycol, low molecular weight poly(alkylene) glycols, and low molecular weight ethers or esters of poly(alkylene) glycols. 15 5. The composition of Claim 3 wherein the poly-ol is glycerol and the ratio of glycerol to water is from '2:1 to 1:2. - 10 47606 6. A composition of Claim 1 comprising, in addition to the hemostatic powder and base, a tackifier. 7. A composition of Claim 6 wherein the tackifier is selected from the group consisting of polyglucosides, gelatin,
5. Collagen gels, polyvinyl pyrrolidone, cellulose esters, oxidized cellulose, water-soluble starches, and sugars. 8. A composition of Claim 7 wherein the tackifier is dextran. 9. A composition of Claim 8 wherein the dextran is 10 present in an amount of from 5 to 10 percent by weight of the composition. 10. A composition of Claim 1 wherein the hemostatic powder comprises from 40 to 95 percent by-Weight fibrin powder and from 5 to 60 percent by weight collagen powder. 15 11. An absorbable hemostatic composition for use in the control of osseous hemorrhage comprising, by weight, 15-25% fibrin powder 15-25% collagen powder
6. 7-10% dextran 20-40% glycerol 20-30% water 11 47606
7. 12. The composition of Claim 11 wherein the particle size of the fibrin powder is less than about 500 microns and the particle size of the collagen powder is less than about 2 mm.
8. 13. The composition of Claim 11 wherein the molecular 5 weight of the dextran is in the range of :from 60,000 to 90,000. Ϊ4. A hemostatic composition as claimed in any of Claims 1 to 13 and substantially as described in the foregoing Examples.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB50503/77A GB1584080A (en) | 1977-12-05 | 1977-12-05 | Absorbable hemostatic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
IE782393L IE782393L (en) | 1979-06-05 |
IE47606B1 true IE47606B1 (en) | 1984-05-02 |
Family
ID=10456141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2393/78A IE47606B1 (en) | 1977-12-05 | 1978-12-04 | Absorbable hemostatic composition |
Country Status (10)
Country | Link |
---|---|
CA (1) | CA1119515A (en) |
DE (1) | DE2852319A1 (en) |
FR (1) | FR2410477A1 (en) |
GB (1) | GB1584080A (en) |
HK (1) | HK34681A (en) |
HU (1) | HU179969B (en) |
IE (1) | IE47606B1 (en) |
IL (1) | IL56110A (en) |
IN (1) | IN149490B (en) |
MY (1) | MY8200056A (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981000516A1 (en) * | 1979-08-31 | 1981-03-05 | Merck Patent Gmbh | Gel containing fibrine and antibiotic for treating infected bones and preparation process thereof |
EP0030583B1 (en) * | 1979-12-18 | 1984-06-13 | Oscobal Ag | Bone replacement material and process for producing a bone replacement material |
DE3014123C2 (en) * | 1980-04-12 | 1982-03-18 | B. Braun Melsungen Ag, 3508 Melsungen | Process for the production of scleroprotein transplants with increased biological stability |
DE3360633D1 (en) * | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
US4439420A (en) * | 1982-11-16 | 1984-03-27 | Ethicon, Inc. | Absorbable hemostatic composition |
US4440789A (en) * | 1982-11-16 | 1984-04-03 | Ethicon, Inc. | Synthetic absorbable hemostatic composition |
US4443430A (en) * | 1982-11-16 | 1984-04-17 | Ethicon, Inc. | Synthetic absorbable hemostatic agent |
USRE32208E (en) * | 1982-11-16 | 1986-07-15 | Ethicon, Inc. | Absorbable hemostatic composition |
ATE31025T1 (en) * | 1983-02-03 | 1987-12-15 | Ethicon Inc | PASTE FOR BLOOD STEASING AND TEMPORARY BREAKDOWN IN BONE TRAUMA. |
EP0166263A1 (en) * | 1984-05-31 | 1986-01-02 | Green Cross Corporation | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
JPS61122222A (en) * | 1984-11-19 | 1986-06-10 | Koken:Kk | Hemostatic agent composed of collagen or gelatin and protamine |
US4891359A (en) * | 1988-12-08 | 1990-01-02 | Johnson & Johnson Patient Care, Inc. | Hemostatic collagen paste composition |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US7189410B1 (en) | 1990-11-27 | 2007-03-13 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
WO1993004732A1 (en) | 1991-09-09 | 1993-03-18 | The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Methods and devices for treating hemophilia and aids |
GB9211432D0 (en) * | 1992-05-29 | 1992-07-15 | Jevco Ltd | Absorbable bone sealant |
US5696101A (en) * | 1996-04-16 | 1997-12-09 | Eastman Chemical Company | Oxidized cellulose and vitamin E blend for topical hemostatic applications |
US6117444A (en) * | 1997-04-10 | 2000-09-12 | Brigham & Women's Hospital | Polyethylene glycol/microfibrillar collagen composite serves as a resorbable hemostatic agent |
US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
DE19858891A1 (en) * | 1998-12-19 | 2000-06-21 | Merck Patent Gmbh | Improved bone seals |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US20060155234A1 (en) | 2002-09-10 | 2006-07-13 | American National Red Cross | Hemostatic dressing |
PL377477A1 (en) | 2002-12-11 | 2006-02-06 | Ferrosan A/S | Gelatine-based materials as swabs |
US7955616B2 (en) | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
CN1856283A (en) | 2003-09-23 | 2006-11-01 | 奥斯治疗有限公司 | Bioabsorbable putty-like hemostatic implants |
WO2005034726A2 (en) | 2003-09-23 | 2005-04-21 | Ortho Therapeutics, Llc | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
DE10357460A1 (en) * | 2003-12-04 | 2005-07-07 | Friedrich-Baur-Gmbh | Bioresorbable material |
WO2005072700A2 (en) * | 2004-01-30 | 2005-08-11 | Ferrosan A/S | Haemostatic sprays and compositions |
AU2005262070B2 (en) | 2004-07-09 | 2011-01-27 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US8603528B2 (en) | 2004-09-16 | 2013-12-10 | Abyrx, Inc. | Compositions and method for the reduction of post-operative pain |
US8506646B2 (en) | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
US8092464B2 (en) | 2005-04-30 | 2012-01-10 | Warsaw Orthopedic, Inc. | Syringe devices and methods useful for delivering osteogenic material |
MX2009001323A (en) | 2006-08-04 | 2009-07-22 | Stb Lifesaving Technologies In | Solid dressing for treating wounded tissue. |
US20090075891A1 (en) | 2007-08-06 | 2009-03-19 | Macphee Martin | Methods and dressings for sealing internal injuries |
US20100331254A1 (en) * | 2007-12-26 | 2010-12-30 | Metamorefix | Pulverized fibrin clots and pharmaceutical compositions containing them |
JP5569398B2 (en) | 2008-02-29 | 2014-08-13 | フェッローサン メディカル ディバイス エー/エス | Device for promoting hemostasis and / or wound healing |
DE202010009512U1 (en) | 2010-05-28 | 2011-01-13 | Hfp Ingredients B.V. | collagen powder |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
AU2013275758B2 (en) | 2012-06-12 | 2015-03-12 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
AU2014283170B2 (en) | 2013-06-21 | 2017-11-02 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
JP6489485B2 (en) | 2013-12-11 | 2019-03-27 | フェロサン メディカル デバイシーズ エイ/エス | Dry composition containing an extrusion enhancing factor |
BR112017007466B1 (en) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | method for preparing a dry composition, method for reconstituting the dry composition, paste, dry composition, container, homeostatic kit, and, using a dry composition |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
CN108261560B (en) * | 2017-01-03 | 2020-12-08 | 张家港唯瀚生物科技有限公司 | Degradable absorbable hemostatic material containing modified starch nanoparticles and application thereof |
CN113144277B (en) * | 2021-04-13 | 2022-06-14 | 武汉理工大学 | Injectable fluid gelatin and preparation method and application thereof |
CN114470307B (en) * | 2022-04-06 | 2022-06-24 | 天新福(北京)医疗器材股份有限公司 | Degradable hemostatic plugging adhesive and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2772999A (en) * | 1952-06-06 | 1956-12-04 | Johnson & Johnson | Hemostatic surgical compositions and dressings |
FR1325128A (en) * | 1962-03-26 | 1963-04-26 | Process for preparing bioplasts which can be used as resorbable prostheses | |
US3523807A (en) * | 1966-11-25 | 1970-08-11 | Mihaly Gerendas | Method of making a cross-linked fibrin prosthesis |
US3742955A (en) * | 1970-09-29 | 1973-07-03 | Fmc Corp | Fibrous collagen derived product having hemostatic and wound binding properties |
US4006220A (en) * | 1975-06-04 | 1977-02-01 | Gottlieb Sheldon K | Compositions and methods useful for repairing depressed cutaneous scars |
-
1977
- 1977-12-05 GB GB50503/77A patent/GB1584080A/en not_active Expired
-
1978
- 1978-08-21 IN IN920/CAL/78A patent/IN149490B/en unknown
- 1978-10-26 CA CA000314424A patent/CA1119515A/en not_active Expired
- 1978-11-20 FR FR7832651A patent/FR2410477A1/en active Granted
- 1978-12-01 HU HU78EI821A patent/HU179969B/en unknown
- 1978-12-04 IE IE2393/78A patent/IE47606B1/en unknown
- 1978-12-04 IL IL56110A patent/IL56110A/en unknown
- 1978-12-04 DE DE19782852319 patent/DE2852319A1/en active Granted
-
1981
- 1981-07-16 HK HK346/81A patent/HK34681A/en not_active IP Right Cessation
-
1982
- 1982-12-30 MY MY56/82A patent/MY8200056A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL56110A (en) | 1981-09-13 |
FR2410477B1 (en) | 1981-11-13 |
GB1584080A (en) | 1981-02-04 |
IL56110A0 (en) | 1979-03-12 |
FR2410477A1 (en) | 1979-06-29 |
MY8200056A (en) | 1982-12-31 |
HK34681A (en) | 1981-07-24 |
HU179969B (en) | 1983-01-28 |
CA1119515A (en) | 1982-03-09 |
DE2852319C2 (en) | 1990-08-16 |
DE2852319A1 (en) | 1979-06-07 |
IN149490B (en) | 1981-12-26 |
IE782393L (en) | 1979-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1119515A (en) | Absorbable hemostatic composition | |
US4439420A (en) | Absorbable hemostatic composition | |
US4440789A (en) | Synthetic absorbable hemostatic composition | |
US4443430A (en) | Synthetic absorbable hemostatic agent | |
US5413792A (en) | Mucoadhesive polysiloxane paste-like base and preparation | |
AU2012318258B2 (en) | Hemostatic compositions | |
US8309131B2 (en) | Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects | |
EP2462957B1 (en) | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects | |
US5696101A (en) | Oxidized cellulose and vitamin E blend for topical hemostatic applications | |
US20090036921A1 (en) | Controlled Viscosity Tissue Adhesive | |
US10342892B2 (en) | Absorbable compositions and methods for their use in hemostasis | |
JP6095675B2 (en) | Non-aqueous compositions for bone hemostasis and methods for using and manufacturing them | |
BR112012011286B1 (en) | implantable folder and its use | |
US20230355835A1 (en) | Polymeric compositions, delivery devices, and methods | |
US2642375A (en) | Hemostatic compositions | |
USRE32208E (en) | Absorbable hemostatic composition | |
CA2913875A1 (en) | Adhesion preventing material | |
EP3664872B1 (en) | Polymeric compositions, delivery devices, and methods | |
JPH02200624A (en) | Dental dressing agent | |
FR2693109A1 (en) | Thixotropic adhesive paste for the protection of the skin, its preparation process and its applications. |